The longevity dividend

The longevity dividend is the argument that a modest slowing of biological aging would yield health and economic benefits exceeding those of eliminating any single disease, and that public research funding should be reallocated accordingly. It was named in 2006 by S. Jay Olshansky, Daniel Perry, Richard Miller, and Robert Butler, who proposed that a seven-year delay in the onset of age-related decline would deliver larger population health gains than curing cancer or heart disease.¹ The argument is the economic face of the Geroscience hypothesis and the principal policy case advanced by the aging-research field.

§The competing-risks argument

The technical core is simple and not much disputed. Age-related diseases compete: a person spared one dies of another. Modelling the elimination of cancer produces a smaller gain in life expectancy than intuition suggests, because the cohort that survives it remains at high risk of cardiovascular disease, dementia, and frailty. Attacking the shared upstream process — the Hallmarks of aging — shifts the whole risk profile rather than removing one branch of it.

The corollary is that the returns to disease-specific research are subject to diminishing returns in a way that returns to geroscience are not. A US modelling study published in 2013 compared a delayed-aging scenario against scenarios in which cancer or heart disease were substantially delayed, and found the aging scenario produced both more years of life and a larger share of those years free of disability, valued at roughly seven trillion dollars in social benefit over fifty years.² That paper is the origin of the dividend's quantitative form.

Why disease-by-disease has a ceiling

Life-table arithmetic implies that eliminating all cancer mortality would add roughly three years to US life expectancy at birth — a real gain, but far smaller than the disease's salience suggests, because the people saved remain old.

§The large valuations

The most-cited figure comes from a 2021 analysis by Andrew Scott, Martin Ellison, and David Sinclair, which valued improvements in the aging process using the standard economic method for pricing mortality risk.³ Their headline results are that a one-year increase in life expectancy achieved by slowing aging is worth on the order of tens of trillions of dollars to the US population, that larger delays are worth proportionally more, and that the value increases as the intervention is applied to successive cohorts because each benefits from the improvements made for the last.

The paper's more interesting finding is comparative. Interventions that extend life without improving health — the Struldbrugg scenario, named for Swift's immortals — are worth much less, and can be worth negative amounts once disability costs are counted. Value depends almost entirely on whether lifespan gains are matched by Healthspan gains, which is the empirical question the field has not answered.

§How the numbers are made

The valuations use the value of a statistical life, a figure derived from what people demonstrably pay to reduce small risks of death — wage premiums for dangerous work, spending on safety equipment. US regulatory agencies use values on the order of ten million dollars per statistical life. Multiplying a per-person willingness to pay by a population produces very large aggregates very quickly.

This is standard practice in regulatory cost-benefit analysis and it is frequently misread. The resulting number is not money that appears in an economy, not tax revenue, and not a budget a government could spend. It is an aggregate of what people would notionally pay for a risk reduction, a measure of welfare rather than of output. Reporting a longevity dividend "worth $38 trillion" alongside figures for national GDP, as coverage routinely does, compares quantities of different kinds.

A separate and more tractable question is the fiscal one: what happens to public budgets. Here the answer depends almost entirely on labour force participation. Extended healthy working life raises output and contributions; extended life without extended work raises pension and care outlays. The dividend argument assumes the former, which is a claim about institutions rather than biology.

§Counterarguments

Morbidity has expanded, not compressed. James Fries proposed in 1980 that medical progress would push the onset of disability toward a fixed lifespan limit, compressing illness into a short terminal period.⁴ Demographic evidence over the following decades has mostly not supported it: gains in life expectancy have generally been accompanied by comparable or larger gains in years lived with disease, and the global gap between total life expectancy and healthy life expectancy has stayed on the order of a decade without narrowing much. Compression of morbidity examines the evidence. If geroprotective drugs behave like the medical advances that preceded them, they would extend both curves together, which is the scenario the valuations price at close to zero.

The dependency ratio. Populations in most high-income and many middle-income countries are aging because fertility has fallen, not because old-age mortality has — the demographic point developed in Overpopulation and life extension. Adding years at the end without changing retirement norms increases the ratio of non-working to working people. Several countries, Denmark and the Netherlands among them, have already indexed statutory pension ages to life expectancy, which converts longevity gains into working years automatically and is the policy the dividend argument implies.

There is no drug to fund. The dividend is an argument for research, not a description of an available intervention, and it should not be confused with the much stronger claim examined in Longevity escape velocity. No pharmaceutical has been shown to slow aging in humans, and the GLP-1 receptor agonists, sometimes offered as a counter-example, treat metabolic disease rather than aging. Metformin and the TAME trial has an observational signal and a trial designed to test it that has never been fully funded; Senolytics have produced modest or null results in the human studies reported so far; Rapamycin has strong mouse data and no completed long-term human outcome trial; unregulated practices such as sauna and cold-water immersion rest on observational cohorts and short-term physiological measures rather than outcome trials. The best-supported geroprotector remains the one described in Exercise as a geroprotector, which requires no research funding at all.

Distribution. A dividend accruing mostly to populations that already live longest would widen the existing gap in life expectancy between rich and poor. Nothing in the argument's structure addresses who receives the years, a problem developed in Access and inequality.

What the estimate is for

Supporters treat the trillion-dollar figures as evidence that aging research is systematically underfunded relative to its expected return. Critics note that the same method applied to any large mortality reduction produces similar numbers, so the figure demonstrates that mortality is valuable rather than that geroscience will deliver.

§Policy implications

The dividend argument has had two concrete effects. It supplied the rationale for treating aging as a legitimate indication in regulatory terms, the reasoning behind the proposed TAME trial designed by Nir Barzilai and colleagues, structured less to demonstrate efficacy than to establish that a regulator would accept an aging-related composite endpoint at all. And it shaped prize competitions and philanthropic funding: the endpoints chosen by XPRIZE Healthspan are functional restoration in muscle, cognition, and immunity rather than lifespan, precisely because functional years are what the economics values.

It has not yet moved public research budgets appreciably. National aging-research institutes remain funded well below cancer and cardiovascular programmes in most countries, and the disease-specific structure of medical research funding has proved resistant to the competing-risks argument that undermines it.

§The unresolved question

Everything turns on whether an intervention that extends life also extends health, and the field has no accepted way to measure that in advance. Aging biomarkers describes the search for a surrogate endpoint that regulators would accept; without one, a trial testing the dividend's central premise would need to run for decades on hard outcomes. Until such a trial exists, the economic case rests on an assumption about biology that the biology has not yet supplied.

§See also

• Geroscience hypothesis
• Compression of morbidity
• Healthspan
• Access and inequality
• Overpopulation and life extension
• Aging biomarkers
• XPRIZE Healthspan
• Longevity escape velocity

§References